Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Friday
Sol-Gel Technologies (NASDAQ:SLGL) will release its Q3 2025 earnings on Friday, November 21, before the market opens. Analysts expect earnings of ($2.09) per share and revenue of $0.30 million. The company previously reported $4.17 EPS for Q2 2025, surpassing estimates. Shares are trading at $35.07, with a market cap of $97.69 million. Analysts have mixed ratings, with a consensus target price of $50.00. Sol-Gel develops dermatological drugs, including Twyneo and Epsolay.
Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) will likely be announcing its Q3 2025 results before the market opens on Friday, November 21st. Analysts expect the company to announce earnings of ($2.09) per share and revenue of $0.30 million for the quarter. Parties may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 21, 2025 at 12:30 PM ET.
Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last released its quarterly earnings data on Friday, August 15th. The company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $4.84. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. The company had revenue of $17.26 million during the quarter, compared to analyst estimates of $2.86 million. On average, analysts expect Sol-Gel Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Get Sol-Gel Technologies alerts:
Sol-Gel Technologies Trading Up 11.3%
Shares of NASDAQ SLGL opened at $35.07 on Friday. The stock has a fifty day moving average price of $33.22 and a 200 day moving average price of $18.61. The company has a market cap of $97.69 million, a P/E ratio of -28.51 and a beta of 1.35. Sol-Gel Technologies has a 12-month low of $4.01 and a 12-month high of $52.26.
Wall Street Analyst Weigh In
Several brokerages recently commented on SLGL. HC Wainwright raised their target price on Sol-Gel Technologies from $6.00 to $50.00 and gave the company a "buy" rating in a report on Monday, October 27th. Weiss Ratings reissued a "hold (c-)" rating on shares of Sol-Gel Technologies in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Sol-Gel Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, November 1st. Finally, Zacks Research raised shares of Sol-Gel Technologies to a "hold" rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $50.00.
Check Out Our Latest Analysis on SLGL
About Sol-Gel Technologies
(Get Free Report)Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Further Reading
- Five stocks we like better than Sol-Gel Technologies
- How to Plot Fibonacci Price Inflection Levels
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- Want to Profit on the Downtrend? Downtrends, Explained.
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- The Significance of Brokerage Rankings in Stock Selection
- Disney’s 2026 Outlook Brightens Under Iger's Magic Touch
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Sol-Gel Technologies Right Now?
Before you consider Sol-Gel Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sol-Gel Technologies wasn't on the list.
While Sol-Gel Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
